133 related articles for article (PubMed ID: 29866231)
1. Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.
Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Khan MA; Shahbaz N
J Coll Physicians Surg Pak; 2018 Jun; 28(6):S89-S90. PubMed ID: 29866231
[TBL] [Abstract][Full Text] [Related]
2. [Lenalidomide desensitization in a patient with 5q- syndrome].
Boudin L; Patient M; Roméo E; Bladé JS; de Jauréguiberry JP
Bull Cancer; 2017 Sep; 104(9):814-816. PubMed ID: 28778340
[No Abstract] [Full Text] [Related]
3. Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.
Colagrande M; Di Ianni M; Coletti G; Peris K; Fargnoli MC; Moretti L; Lapecorella M; Tabilio A
Int J Hematol; 2009 Jan; 89(1):76-79. PubMed ID: 19052692
[TBL] [Abstract][Full Text] [Related]
4. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
5. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
Almeida A; Fenaux P; Garcia-Manero G; Goldberg SL; Gröpper S; Jonasova A; Vey N; Castaneda C; Zhong J; Beach CL; Santini V
Leuk Lymphoma; 2018 Sep; 59(9):2135-2143. PubMed ID: 29322849
[TBL] [Abstract][Full Text] [Related]
7. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
[TBL] [Abstract][Full Text] [Related]
10. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
[TBL] [Abstract][Full Text] [Related]
12. [A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].
Yamada M; Kuroda H; Jomen W; Yoshida M; Miura S; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Nagashima K; Arihara Y; Hirako T; Kato J
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2593-7. PubMed ID: 24335378
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
14. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Mallo M; Del Rey M; Ibáñez M; Calasanz MJ; Arenillas L; Larráyoz MJ; Pedro C; Jerez A; Maciejewski J; Costa D; Nomdedeu M; Diez-Campelo M; Lumbreras E; González-Martínez T; Marugán I; Such E; Cervera J; Cigudosa JC; Alvarez S; Florensa L; Hernández JM; Solé F
Br J Haematol; 2013 Jul; 162(1):74-86. PubMed ID: 23614682
[TBL] [Abstract][Full Text] [Related]
15. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
[TBL] [Abstract][Full Text] [Related]
16. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
17. Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.
Mortensen TB; Frederiksen H; Marcher CW; Preiss B
BMJ Case Rep; 2017 Jan; 2017():. PubMed ID: 28052942
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Takahashi K; Cortes J; Pierce S; Abruzzo L; Kantarjian H; Verstovsek S
Leuk Res; 2013 May; 37(5):552-5. PubMed ID: 23391517
[TBL] [Abstract][Full Text] [Related]
20. 5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Ortega M; Mallo M; Solé F; Sánchez-Morata C; López-Andreoni L; Martínez-Morgado N; Gironella M; Valcárcel D; Vallespí T
Leuk Res; 2013 Oct; 37(10):1248-50. PubMed ID: 23891188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
